ACE inhibitor pathway (WP468)

Danio rerio

The renin-angiotensin-aldosterone system (RAAS) is central to the control of blood pressure and the target of several types of anti-hypertensive drugs. This pathway depicts a simplified representation of the pharmacodynamics (PD) of RAAS-acting drugs including candidate genes for the pharmacogenomics (PGx) of ACE inhibitors, angiotensin receptor blockers (ARBs), renin inhibitor aliskiren and aldosterone receptor antagonists. Source: PharmGKB (
last edited


Caroline F. Thorn , Thomas Kelder , Kristina Hanspers , Egon Willighagen , Christine Chichester , Martina Summer-Kutmon , and Eric Weitz

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Danio rerio



Pathway Ontology: ACE inhibitor drug pathway


Label Type Compact Identifier Comment
Bradykinin Metabolite hmdb:HMDB0004246
Aldosterone Metabolite kegg.compound:C01780
ACE Inhibitor Metabolite chebi:35457
Angiotensin II Metabolite hmdb:HMDB0001035
Angiotensin I Metabolite pubchem.compound:3081372
ren GeneProduct ncbigene:405786
bdkrb2 GeneProduct ncbigene:368199
agt GeneProduct ncbigene:322485
kng1 GeneProduct ncbigene:449808
agtr1 GeneProduct ncbigene:561935
agtr2 GeneProduct ncbigene:503772
ace2 GeneProduct ncbigene:492331
ace2 GeneProduct ncbigene:492331


  1. The emerging role of ACE2 in physiology and disease. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus ADME, et al. J Pathol. 2007 May;212(1):1–11. PubMed Europe PMC Scholia